



Pergamon

Tetrahedron Letters 41 (2000) 2073–2076

TETRAHEDRON
LETTERS

Neomarinone, and new cytotoxic marinone derivatives, produced by a marine filamentous bacterium (actinomycetales)

Ingo H. Hardt, Paul R. Jensen and William Fenical *

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California-San Diego, La Jolla, CA 92093-0204, USA

Received 1 December 1999; accepted 13 January 2000

Abstract

Neomarinone (**1**), a novel metabolite possessing a new sesquiterpene- and polyketide-derived carbon skeleton, and several derivatives, **3–5**, of the marinone class of naphthoquinone antibiotics, were isolated from the fermentation broth of a taxonomically-novel marine actinomycete (strain #CNH-099). The structures of the new compounds were determined by comprehensive NMR and mass spectral analyses. Neomarinone (**1**) and several of the marinone derivatives were shown to be moderately cytotoxic toward human cancer cells in *in vitro* testing. © 2000 Elsevier Science Ltd. All rights reserved.

Keywords: marine bacteria; naphthoquinone; mixed biosynthesis.

Marine microorganisms have been recognized as a new source for the production of bioactive secondary metabolites. The large numbers, and diversity, of marine bacteria suggest that this resource will be of significant importance in the discovery of new drugs.¹ Indeed, over the past few years a significant diversity of antibiotics and antitumor agents has been identified.² In this paper we report the isolation of several cytotoxic metabolites related to marinone, a novel marine actinomycete-derived metabolite reported earlier.³ The new compounds are produced by a marine bacterium found in a sediment sample taken at –1 m in Batiquitos Lagoon, North of San Diego, CA. The bacterium (strain #CNH-099)⁴ was cultured in 26 L scale⁵ and the culture was repeatedly extracted with ethyl acetate. Concentration of the extract yielded 2.15 g of crude extract which was fractionated by silica column methods, followed by repeated silica HPLC (% EtOAc in isooctane) to yield neomarinone (**1**, 1 mg/L, 35%), marinone (**2**, 1 mg/L, 30%), isomarinone (**3**, 0.5 mg/L, 30%), hydroxydebromomarinone (**4**, 1 mg/L, 50%), and methoxydebromomarinone (**5**, 1 mg/L, 50%). The structure elucidations of the new marinone derivatives **1** and **3–5** were accomplished by analysis of MS and NMR data and comparison with the published data for the previously reported metabolites marinone (**2**) and debromomarinone.³ Neomarinone (**1**)^{6a} analyzed for C₂₆H₃₂O₅ by HR-FABMS and ¹³C NMR methods (Table 1). The UV spectrum of **1** showed

* Corresponding author. Tel: (858)534-2133; fax: (858)558-3702; e-mail: wfenical@ucsd.edu (W. Fenical)

Table 1
NMR data for neomarinone (**1**), marinone (**2**) and derivatives (**3–5**)

C#	1		2		3		4		5	
	¹³ C	¹ H	¹³ C	¹ H	¹³ C	¹ H	¹³ C	¹ H	¹³ C	¹ H
1	153.5	10.27 (s)-OH	150.2	-	152.3	-	153.8	-	153.8	-
2	180.3	-	181.9	-	182.0	-	181.7	-	181.4	-
3	131.5	-	108.8	-	107.0	-	107.5	-	107.4	-
4	107.9	7.05 (s)	162.6 ^a	12.55 (s)-OH	159.6	12.54 (s)-OH	163.4	11.88 (s)-OH	163.2	11.86 (s)-OH
5	157.6	10.71(s)-OH	106.0	6.64 (s)	101.7	-	106.2	6.45 (d, 2.4)	106.1	6.46 (d, 2.2)
6	127.3	-	162.7 ^a	11.99 (bs)-OH	161.8	12.11 (bs)-OH	165.6	11.25 (bs)-OH	165.4	11.29 (bs)-OH
7	159.9	-	104.1	-	107.4	7.09 (s)	108.5	6.94(d, 2.4)	108.4	6.93 (d, 2.2)
8	107.9	-	131.0 ^b	-	132.1	-	134.9	-	134.7	-
9	182.7	-	182.4	-	182.4	-	182.5	-	182.1	-
10	120.3	-	124.5	-	123.1	-	125.0	-	127.7	-
11	15.1	1.30 (d, 6.3)	30.4	3.37 (m)	30.3	3.35(m)	116.1	-	115.5	-
12	86.3	4.65 (q, 6.3)	119.7	5.84 (d, 4.4)	120.1	5.95 (d, 5.0)	137.6	7.27(s)	134.2	7.28
13	46.0	-	135.7	-	135.3	-	65.6	4.63 (bs)-OH	70.3	-
14	31.0	1.86 (m)	29.3	1.97 (m)	29.1	1.84 (m)	35.7	1.69/1.45 (m)	33.1	1.83/1.40 (m)
15	123.9	5.36 (bs)	19.8	1.89/1.17 (m)	19.7	1.87/1.18 (m)	19.4	1.60/1.51 (m)	19.0	1.59/1.45 (m)
16	138.9	-	36.8	1.86 (m)	36.6	1.86 (m)	39.3	2.34(ddd,10.3, 5.4, 2.0)	40.4	2.40 (m)
17	39.6	-	82.0	-	82.4	-	83.0	-	83.2	-
18	30.5	1.31/1.16(m)	36.1	1.53 (m)	35.9	1.54 (m)	38.4	1.77/1.70 (m)	38.2	1.75 (m)
19	25.0	1.92/1.83(m)	22.0	1.94 (m)	22.0	1.94 (m)	20.9	2.18/2.08 (m)	20.9	2.13 (m)
20	26.6	1.37 (m)	123.8	5.04 (bt, 6.5)	123.8	5.04 (bt,6.8)	124.0	5.16 (bt, 6.5)	123.7	5.16 (bt, 7.0)
21	32.7	1.70 (m)	131.1 ^b	-	131.1	-	131.4	-	131.2	-
22	15.6	0.78 (d, 6.8)	25.3	1.56 (s)	25.3	1.55 (s)	25.4	1.66 (s)	25.4	1.66 (s)
23	20.9	0.74 (s)	17.3	1.50 (s)	17.3	1.50 (s)	17.5	1.60 (s)	17.4	1.60 (s)
24	18.7	1.52 (s)	21.6	1.41 (s)	21.6	1.43 (s)	18.6	1.09 (s)	18.4	1.09 (s)
25	19.7	1.14 (s)	23.4	1.62 (s)	23.3	1.61 (s)	30.8	1.24 (s)	25.2	1.25 (s)
26	8.5	1.83 (s)							49.4	3.13 (s)

¹³C spectra were recorded in DMSO-*d*₆ at 100 MHz (**1** and **4** at 125 MHz). ¹H spectra were recorded at 300 MHz (**1** and **4** at 500 MHz). All data are referenced to residual solvent at δ 39.5 and δ 2.49, respectively. ^{a,b} Assignments may be interchanged. All assignments were made on the basis of COSY, DEPT and HMBC/HMQC data.

Methoxydebromomarinone (**5**) analyzed for C₂₆H₃₀O₆ by HR-FABMS and by ¹³C NMR methods. As in **4**, the overall spectral data for **5**^{6d} showed the molecule to be a modified marinone structure. NMR data allowed the modification to be localized in the side-chain cyclohexene ring. Similar to **4**, the structure of **5** was assigned as the C-13 methoxy analog. The relative stereochemistry at C-13 in **5**, with the methyl in the up (β) position, was determined by a strong NOE correlation between H-25 and H-16.

Neomarinone and the new marinone derivatives are all derived from a mixed biosynthetic pathway apparently involving polyketide and terpene pathways. Connection of the sesquiterpenoid side-chain to the naphthoquinone core occurs on the non-quinone side in neomarinone. There are only a few examples where similar metabolites produced by mixed biosynthesis have been observed. Examples are the monoterpene-substituted naphthoquinones, naphterpin⁷ and naphthogeranine A.⁸ Also, the monoterpene derivatives, furaquinocins A–H, which are similar to neomarinone have been reported.^{9,10} The origin of the sesquiterpenoid side-chain in **1** appears complex, possibly being derived from a cation-induced methyl migration as observed in the trichothecenes.¹¹ Neomarinone (**1**), and the marinones **3–5**, displayed

moderate in vitro cytotoxicity, IC_{50} =ca. 8 μ g/mL against HCT-116 colon carcinoma. In addition, neomarinone generated a mean IC_{50} value of 10 μ M in the NCI's 60 cancer cell line panel.

Acknowledgements

This work was supported by the National Institutes of Health, National Cancer Institute, under grant CA44848. I.H. thanks the Fonds der Chemischen Industrie (FCI), Verband der angestellten Akademiker (VAA) and Deutsche Forschungsgemeinschaft (DFG) for support in the form of postdoctoral fellowships. We appreciate the expert technical assistance provided by Christopher Kauffman.

References

- (a) Jensen, P. R.; Fenical, W. *J. Ind. Microbiol.* **1996**, *17*, 346. (b) Fenical, W. *Chem. Rev.* **1993**, *93*, 1673. (c) Okami, Y. *J. Mar. Biotech.* **1993**, *1*, 59.
- (a) Fenical, W. *Chem. Rev.* **1993**, *93*, 1883. (b) Davidson, B. S. *Curr. Opin. Biotechnol.* **1995**, *6*, 284. (c) Liberra, K.; Lindequist, U. *Pharmazie* **1995**, *50*, 583.
- Pathirana, C.; Jensen, P. R.; Fenical, W. *Tetrahedron Lett.* **1992**, *33*, 7663.
- Bacterial strain CNH-099 was isolated from a sediment sample (collected at -1 m, Batiqitos Lagoon) using serial dilution and plating techniques on medium A1 (1.6% agar, 1% starch, 0.4% yeast extract, 0.2% peptone, 100% seawater). As in the original strain producing marinone (CNB-384), strain CNH-099 could not be assigned to any known actinomycete genus by fatty acid methyl ester (FAME) analysis (Microbial ID Inc., Newark, DE).
- Bacterial strain CNH-099 was cultivated in 26×1 L volumes in Fernbach flasks. The flasks were shaken at 230 rpm at 23°C for 8–10 days.
- (a) *Spectral data for neomarinone (1)*: HR-FABMS: 424.2265 [M]⁺; calcd for C₂₆H₃₂O₅: 424.2250 (Δ 3.6ppm) [α]_D²⁵ +86° (c=0.5, MeOH); IR (film): 3299, 2923, 1659, 1630, 1606, 1569, 1418, 1379, 1347, 1302, 1185, 1052; UV [λ _{max} (ε)]: (MeOH): 398 (2700), 312 (7800), 263 (13900), 259 (sh 13500), 213 nm (19800); (MeOH+KOH): 525 (1100), 358 (6000), 289 (19500), 229 nm (15400). *Spectral data for marinone (2)*: HR-FABMS: [M]⁺ m/z 486.1033; calcd for C₂₅H₂₇O₅⁷⁹Br: 486.1042 (Δ 1.8 ppm), [α]_D²⁵ -170° (c=0.15, MeOH); IR (film): 3250, 2925, 1639, 1603, 1388, 1274, 1221, 1037 cm⁻¹; UV [λ _{max} (ε)]: (MeOH+HCl): 435 (1400), 395 (1500), 307 (5200), 268 (6900), 202 nm (18100), (MeOH+KOH): 510 (3700), 385 (2300), 335 (5400), 298 (9900), 234 nm (15600); (b) *Spectral data for isomarinone (3)*: HRCIMS (NH₃): [M+H]⁺ m/z 487.1094; calcd for C₂₅H₂₈O₅⁷⁹Br: 487.1120 (Δ 5.4 ppm); [α]_D²⁵ -120° (c=0.2, MeOH); (film): 3226, 2925, 1634, 1589, 1451, 1378, 1327, 1225, 1045 cm⁻¹; UV [λ _{max} (ε)]: (MeOH+HCl): 390 (1500), 312 (4700), 270 (8100), 265 (8000), 206 nm (17000), (MeOH+KOH): 513 (2000), 385 (2000), 327 (4100), 295 (9500), 230 nm (12200); (c) *Spectral data for hydroxydebromomarinone (4)*: HR-FABMS: [M]⁺ m/z 424.1870; calcd for C₂₅H₂₈O₆: 424.1886 (Δ 3.8 ppm); [α]_D²⁵ +280° (c=0.2, MeOH); IR (film): 3243, 2925, 1632, 1594, 1561, 1453, 1380, 1326, 1227 cm⁻¹; UV [λ _{max} (ε)]: (MeOH+HCl): 460 (2600), 392 (2800), 328 (7000), 283 (18100), 275 (17000), 228 (16000), 211 nm (18900), (MeOH+KOH): 525 (4700), 358 (8100), 299 (13400), 249 (20700), 238 nm (20300); (d) *Spectral data for methoxydebromomarinone (5)*: HR-FABMS: [M]⁺ m/z 438.2053; calcd for C₂₆H₃₀O₆: 438.2042 (Δ 2.4 ppm); [α]_D²⁵ +140° (c=0.1, MeOH); IR (film): 3250, 2933, 1631, 1605, 1562, 1454, 1327, 1231 cm⁻¹; UV [λ _{max} (ε)]: (MeOH+HCl): 455 (2100), 385 (2700), 325 (sh 5300), 308 (5900), 283 (12400), 275 (12000), 228 (sh 13200), 208 nm (17800), (MeOH+KOH): 525 (3000), 354 (6000), 298 (10000), 250 nm (15900).
- Shin-Ya, K.; Imai, S.; Furihata, K.; Hayakawa, Y.; Kato, Y.; VanDuyne, G. D.; Clardy, J.; Seto, H. *J. Antibiot.* **1990**, *43*, 444.
- Wessels, P.; Göhr, A.; Zeeck, A.; Drautz, H.; Zähler, H. *J. Antibiot.* **1991**, *44*, 1013.
- Funayama, S.; Ishibashi, M.; Anraku, Y.; Komiyama, K.; Omura, S. *Tetrahedron Lett.* **1989**, *30*, 7427.
- Ishibashi, M.; Funayama, S.; Anraku, Y.; Komiyama, K.; Omura, S. *J. Antibiot.* **1991**, *44*, 391.
- Cane, D. E.; Xue, Q.; Fitzsimons, B. C. *Biochemistry* **1996**, *35*, 12369.